
CRNX
Healthcare · Biotechnology · $9.01B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · +7.1% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 3, 2026 | After the close | -1.23 | -1.14 | +7.3% |
| May 7, 2026 | After the close | -1.20 | -1.23 | -2.5% |
| Feb 26, 2026 | Time not confirmed | -1.37 | -1.29 | +5.8% |
| Nov 6, 2025 | After the close | -1.25 | -1.38 | -10.4% |
| Aug 7, 2025 | After the close | -1.13 | -1.23 | -8.8% |
| May 8, 2025 | After the close | -0.95 | -1.04 | -9.5% |
| Feb 26, 2025 | Before the open | -0.89 | -0.88 | +1.3% |
| Nov 12, 2024 | After the close | -0.91 | -0.96 | -5.5% |
| Aug 8, 2024 | After the close | -0.86 | -0.94 | -9.3% |
| May 9, 2024 | After the close | -0.81 | -0.93 | -14.8% |
| Feb 28, 2024 | After the close | -0.86 | -0.90 | -4.7% |
| Nov 7, 2023 | After the close | -0.88 | -1.01 | -14.8% |
| Aug 8, 2023 | Before the open | -0.85 |
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid…
| -0.94 |
| -10.6% |
| May 4, 2023 | After the close | -0.83 | -0.85 | -2.4% |
| Feb 28, 2023 | After the close | -0.82 | -0.84 | -2.4% |
| Nov 14, 2022 | Before the open | -0.83 | -0.78 | +6.0% |
| Aug 12, 2022 | Before the open | -0.66 | -0.81 | -22.7% |
| May 12, 2022 | After the close | -0.45 | -0.73 | -62.2% |
| Mar 30, 2022 | After the close | -0.62 | -0.68 | -9.7% |
| Nov 5, 2021 | Before the open | -0.73 | -0.73 | 0.0% |
| Aug 10, 2021 | After the close | -0.63 | -0.70 | -11.1% |
| May 6, 2021 | After the close | -0.66 | -0.69 | -4.5% |
| Mar 30, 2021 | After the close | -0.58 | -0.66 | -13.8% |
| Nov 6, 2020 | Before the open | -0.52 | -0.56 | -7.7% |
| Aug 7, 2020 | Before the open | -0.56 | -0.53 | +5.4% |
| May 8, 2020 | Before the open | -0.63 | -0.71 | -12.7% |
| Mar 9, 2020 | After the close | -0.63 | -0.60 | +4.8% |
| Nov 12, 2019 | After the close | -0.53 | -0.60 | -13.2% |
| Aug 13, 2019 | After the close | -0.45 | -0.51 | -13.3% |
| May 13, 2019 | After the close | -0.41 | -0.37 | +9.8% |
| Mar 13, 2019 | After the close | -0.41 | -0.35 | +14.6% |
| Nov 13, 2018 | After the close | -0.36 | -0.38 | -5.6% |
| Aug 30, 2018 | After the close | -0.29 | -2.41 | -731.0% |
| May 3, 2018 | Time not confirmed | — | -0.42 | — |